Nanobiotix announces FDA accepts protocol changes to cancer study

May 4, 2026 5:29 PM

Nanobiotix (NASDAQ: NBTX) announced the FDA accepted a protocol amendment to its ongoing Phase 3 head and neck cancer study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found